The company’s second foray with a PI3K inhibitor shows signs of additive activity, but investors punish it all the same.
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.